Evidence map›Paper›PMID 36299923›Full record

ArticleCureus2022

Cutaneous Basal Cell Carcinoma In Situ: A Case Series.

Philip R Cohen

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Philip R CohenDermatology, University of California, Davis Medical Center, Sacramento, USA.
University of California Davis Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Basal cell carcinoma, squamous cell carcinoma, and melanoma are three types of skin cancers. Skin cancers present as either non-invasive malignancies or invasive neoplasms. The non-invasive malignancies are referred to as carcinoma in situ; they only have cancer cells that are restricted to the epidermis and are not present as single tumor cells or independent nests of malignant cells in the underlying dermis. In contrast, invasive neoplasms demonstrate individual malignant cells or aggregates of tumor cells or both that are found in the dermis; in addition, cancer cells may also be located in the overlying epidermis. The features of three men with basal cell carcinoma in situ of the skin are described in this case series. Each of their tumors morphologically appeared as a red, scaly or non-scaly, and superficial plaque on the abdomen or the back; the neoplasm was successfully treated without recurrence by either surgical excision or by topical 5% imiquimod cream. Cutaneous basal cell carcinoma in situ has characteristic morphologic and pathologic findings. Clinically, cancer most commonly appears as a thin, smooth-surfaced or scaly, and as an erythematous plaque on the trunk. Microscopic examination shows multiple sites of basaloid tumor cells that either nearly filled the epidermis and/or replaced the lower layers of the epidermis; the aggregates of tumor cells may expand the epidermis and display slight extension into the papillary dermis. However, there is no non-contiguous invasion of the tumor cells from the overlying epidermis into the underlying dermis. Palisading of the peripheral tumor cells is noted; in addition, focally, retraction of the dermal stroma from the tumor is also frequently present. Lymphocytic inflammation may also be present in the upper dermis. Similar to the reported patients, since basal cell carcinoma in situ of the skin is only localized to the epidermis, several therapeutic modalities are available to effectively treat the cancer. However, if the basal cell carcinoma in situ represents the superficial portion of a basal cell carcinoma of mixed histology, tumor persistence or recurrence may occur if a more conservative approach to treatment is utilized that does not adequately treat the unsuspected and more aggressive pathologic subtype of basal cell carcinoma in the underlying dermis. In summary, basal cell carcinoma in situ of the skin has a unique clinicopathologic correlation of morphology, histology, tumor biology, and response to treatment; indeed, tumors that were previously classified as superficial basal cell carcinoma are more appropriately designated as cutaneous basal cell carcinoma in situ.

Indexed as

basal cell carcinomabasal cell carcinoma in situcancercutaneousin situmelanomamelanoma in situskinsquamous cell carcinomasquamous cell carcinoma in situ

Identifiers

PMID36299923
PMCPMC9588167
OpenAlexW4297896490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.